 AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. The new results come from the EMERALD-3 study, testing a combination of PD-L1 inhibitor Imfinzi (durvalumab) with AZ's CTLA4 inhibitor Imjudo (tremelimumab) – as well as Eisai's multikinase inhibitor Lenvima (lenvatinib) – as a first-line treatment for unresectable hepatocellular carcinoma (HCC) patients who are eligible for a procedure known as transarterial chemoembolisation (TACE). 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
